Citations

Showing 10 of 108094 citations.

P685: REAL WORLD EVIDENCE OF IMPACT OF ATRIAL FIBRILLATION ON CLINICAL AND ECONOMIC OUTCOMES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Yang, K., Liu, T., Tang, B., Chanan‐Khan, Asher , Yang, K., Tang, B

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 581-582

10.1097/01.hs9.0000845624.04306.b3 Get It

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
Foran, James M. , Watts, Justin M. , Stein, Eytan M. , Fathi, Amir T. , Prince, Gabrielle T., Stone, R. M., Patel, Prapti A. , Arellano, Martha , Pigneux, A., Baratam, Praneeth , Thomas, Xavier , Lemieux, I. R., Bai, Xiatong , Kapsalis, S. M., Garcia‐Manero, G., Sallman, David A. , DiNardo, Courtney D. , Botton, Stéphane de , Roboz, Gail J. , Erba, Harry Paul , Stuart, Robert K.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 660-661

10.1097/01.hs9.0000845944.18977.d1 Get It

P775: CLINICAL OUTCOMES AND SOCIOECONOMIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE UNITED STATES USING THE NATIONAL CANCER DATABASE: 2004-2017
Mclaughlin, N., Ruan, G., Wudhikarn, Kitsada, Al-Kali, A., Tefferi, A., Gangat, N., Go, R., Patnaik, M., Shah, M., Al-Kali, A.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 670-671

10.1097/01.hs9.0000845984.24573.73 Get It

P656: INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY
Koehler, A., Moise, M., Call, T., Rabe, K., Achenbach, S., Crusan, D. J., Bailey, K., Petterson, T., Ding, W., Kenderian, S., Leis, J., Wang, Y., Muchtar, E., Hampel, P., Schwager, S., Slager, S., Kay, N., Ashrani, A., Parikh, S., Rabe, K. G., Crusan, Daniel J. , Leis, Joe, Wang, Yucai , Hampel, Paul J. , Slager, Susan, Parikh, Sameer A.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 554-555

10.1097/01.hs9.0000845508.29001.67 Get It

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
Susswein, Lisa R. , Roberts, Maegan E. , Yang, Hana , Marshall, Megan L. , Hiraki, Susan , Berkofsky‐Fessler, Windy, Gupta, Sounak , Shen, Wei , Dunn, Carolyn, Huang, Huaizhi , Yadav, Siddhartha , Hruska, Kathleen S. , Chen, Chen , Lumby, Carolyn A. , Hu, Chunling , Hiraki, Susan , Gupta, Sounak , Shen, Wei , Dunn, Carolyn A, Na, Jie , Domchek, Susan M , Yadav, Siddhartha , Monteiro, Alvaro N , Hart, Steven N , Couch, Fergus J. , Chen, C , Huang, Huaizhi , Lumby, Carolyn A , Roberts, Maegan E , Hu, Chunling , Na, Jie , Domchek, Susan M. , Monteiro, Álvaro N.A. , Polley, Eric C. , Hart, Steven N. , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | June 23, 2022 | Volume: 28 | Issue: 17 | Pages: 3742-3751

10.1158/1078-0432.ccr-22-0203 | PMID 35736817 Get It

Abstract Purpose: The identification of variants of uncertain significance (VUS) in the BRCA1 and BRCA2 genes by hereditary cancer testing poses great challenges for the clinical management of variant carriers. The ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) variant classification framework, which incorporates multiple sources of evidence, has the potential to establish the clinical relevance of many VUS. We sought to classify the clinical relevance of 133 single-nucleotide substitution variants encoding missense variants in the DNA-binding domain (DBD) of BRCA2 by incorporating results from a validated functional assay into an ACMG/AMP-variant classification model from a hereditary cancer–testing laboratory. Experimental Design: The 133 selected VUS were evaluated using a validated homology-directed double-strand DNA break repair (HDR) functional assay. Results were combined with clinical and genetic data from variant carriers in a rules-based variant classification model for BRCA2. Results: Of 133 missense variants, 44 were designated as non-functional and 89 were designated as functional in the HDR assay. When combined with genetic and clinical information from a single diagnostic laboratory in an ACMG/AMP-variant classification framework, 66 variants previously classified by the diagnostic laboratory were correctly classified, and 62 of 67 VUS (92.5%) were reclassified as likely pathogenic (n = 22) or likely benign (n = 40). In total, 44 variants were classified as pathogenic/likely pathogenic, 84 as benign/likely benign, and 5 remained as VUS. Conclusions: Incorporation of HDR functional analysis into an ACMG/AMP framework model substantially improves BRCA2 VUS re-classification and provides an important tool for determining the clinical relevance of individual BRCA2 VUS.
P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
Johnson, I., McCullough, K., Farrukh, F., Al‐Kali, Aref , Begna, Kebede H. , Mangaonkar, Abhishek A. , Litzow, Mark R. , Shah, Manisha , Patnaik, Mrinal M. , Pardanani, Animesh , Tefferi, Ayalew, Gangat, Naseema , Alkhateeb, Hassan B. , Hogan, William J. , Shah, M., Tefferi, Ayalew

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 443-444

10.1097/01.hs9.0000845064.44923.05 Get It

P651: VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY
Hampel, P., Parikh, S., Wierda, W., Ferrajoli, A., Jain, N., Burger, J., Call, T., Wang, Y. , Kenderian, S., Ding, W., Hampel, Paul J. , Parikh, Sameer A. , Wierda, William G. , Jain, N., Wang, Y., Kenderian, S., Thompson, Philip A

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 549-550

10.1097/01.hs9.0000845488.18043.aa Get It

P540: PEVONEDISTAT, AZACITIDINE AND VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA– A PHASE I STUDY
Kaufmann, S., Saliba, A., Szabo, A., Michaelis, L., Abedin, S., Runaas, L., Carlson, K., Maldonado-Schmidt, S., Hinman, Alex, Thomas, A., Baim, A., Litzow, M., Atallah, E., Murthy, Guru Subramanian Guru , Saliba, Antoine N. , Hinman, Alexander, Litzow, Mark R. , Atallah, Ehab

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 439-440

10.1097/01.hs9.0000845048.06102.ff Get It

Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma
Tang, Xinyi , Anagnostou, Theodora , Wu, Xiaosheng , Krull, Jordan E. , Wenzl, Kerstin , Mondello, Patrizia , Bhardwaj, Vaishali , Wang, Junwen , Novak, Anne J. , Ansell, Stephen M. , Anagnostou, Theodora , Krull, Jordan E , Mondello, Patrizia , Bhardwaj, Vaishali , Ansell, Stephen M , Wang, Junwen , Yang, Zhi-Zhang , Kim, Hyo Jin , Yu, Yue , Chen, Jun

Mayo Clinic

Clinical Cancer Research | June 23, 2022 | Volume: 28 | Issue: 19 | Pages: 4322-4335

10.1158/1078-0432.ccr-22-0977 | PMID 35686915 Get It

Abstract Purpose: Regulatory T-cells (Treg) are essential to Tregs homeostasis and modulate the antitumor immune response in patients with lymphoma. However, the biology and prognostic impact of Tregs in splenic marginal zone lymphoma (SMZL) have not been studied. Experimental Design: Biopsy specimens from 24 patients with SMZL and 12 reactive spleens (rSP) from individuals without lymphoma were analyzed by using CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing), CyTOF (mass cytometry) analysis, and flow cytometry to explore the phenotype, transcriptomic profile, and clinical significance of intratumoral Tregs and their subsets. The biological characteristics and cell signaling pathways of intratumoral Treg subsets were confirmed by in vitro functional assays. Results: We found that Tregs are more abundant in SMZL patients' spleens than rSP, and Tregs from patients with SMZL and rSP can be separated into CD161+Treg and CD26+Treg subsets. CD161+Tregs are increased in SMZL but have dysregulated immune function. We found that CD161+Treg and CD26+Tregs have unique gene expression and phenotypic profiles and are differentially correlated with patient outcomes. Specifically, increased CD161+Tregs are significantly associated with a favorable prognosis in patients with SMZL, whereas CD26+Tregs are associated with a poor prognosis. Furthermore, activation of the IL2/STAT5 pathway contributes to the induction of CD26+Tregs and can be reversed by STAT5 inhibition. Conclusions: IL2/STAT5-mediated expansion of CD26+Tregs contributes to a poor clinical outcome in SMZL and may represent a therapeutic opportunity in this disease.